Respiratory syncytial virus pre-fusion glycoprotein F
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2023
- First approval year
- 2023
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Respiratory syncytial virus pre-fusion glycoprotein F
- abrysvo
- Abrysvo
- arexvy
- Arexvy
- recombinant stabilized rsv a prefusion f antigen component of abrysvo
- Recombinant stabilized rsv a prefusion f antigen component of abrysvo
- recombinant stabilized rsv b prefusion f antigen component of abrysvo
- Recombinant stabilized rsv b prefusion f antigen component of abrysvo
- abrysvo
- Abrysvo
- ABRYSVO
- ABRYSVO®
- AREXVY
- Arexvy (1 dose total)
- Arexvy (2 doses total)
- Arexvy (3 doses total)
- Arexvy 120 mcg
- recombinant respiratory syncytial virus pre fusion f protein antigen
- Recombinant respiratory syncytial virus pre-fusion f protein antigen
- recombinant stabilized rsv a prefusion f antigen
- Recombinant stabilized rsv a prefusion f antigen
- recombinant stabilized rsv b prefusion f antigen
- Recombinant stabilized rsv b prefusion f antigen
- respiratory syncytial virus pre fusion glycoprotein f
- Respiratory syncytial virus pre-fusion glycoprotein f
- ChEMBL ID
- CHEMBL6068489
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- vir-
Mechanisms of action
- Mechanism
- Fusion glycoprotein F0 vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Fusion glycoprotein F0
- Protein identifier
- Q89535
Open Targets mechanisms
- Mechanism
- Fusion glycoprotein F0 vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Fusion glycoprotein F0
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Respiratory Syncytial Virus Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001413
- Subject identifier
- D018357
- Condition identifier
- EFO_1001413
- Condition identifier
- MONDO_0001577
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (17)
- A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
- Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
- Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá
- Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants
- Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset
- First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
- Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
- Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
- Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.
- Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination
- RSV Vaccination in Immunocompromised Patients.
- RSV Vaccination to Reduce Recurrent AECOPD
- Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
- Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women
- STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
- Vaccine Responses in Patients With B Cell Malignancies